127 / 144
127
(consultar capítulo 15: Qual o papel dos corticóides no EMD?)
Terapêutica intravítrea com Anti-VEGF e Corticosteróides
DRCR.netProtocolo U
Estudo fase II, combinação de dexametasona intravítrea e RBZ 0.3mg na acui-
dade visual e espessura macular (avaliada no OCT)
versus
RBZ em monoterapia
no EMD persistente com diminuição da acuidade visual, apesar de 3 injecções
prévias de anti-VEGF (RBZ, BZB ou AFT) nas 20 semanas prévias
16
.
Referências
1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for dia-
betic macular edema, Early Treatment Diabetic Retinopathy Study Report no.1. Arch
Ophthalmol. 1985;103,1796-1806.
2. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, Cunha-Vaz JG, Chong
NV. Prospective randomized controlled trial comparing subthreshold micropulse diode
laser photocoagulation and conventional green laser for clinically diabetic macular
edema. Br J Ophthalmol. 2009 Oct;93(10):1341-4. doi: 10.1136/bjo.2008.146712.
Epub 2008 Dec 3.
3. RISE/RIDE: Brown DM, Nguyen QD, Marcus DM, et al. Long - term outcomes of ranibi-
zumab therapy for diabetic macular edema: the 36 - month results from phase III trials:
RISE and RIDE. Ophthalmology. 2013;120(10): 2013-2020.
4. Rjendram R, et al. A prospective randomized trial of intravitreal ranibizumab or laser
therapy in the management of diabetic macular edema: 24 month data, Report 3. Arch
Ophthalmol. 2012;130(8):972-979.
Tabela 1
Ensaios clínicos com corticosteróides